This is attributed to the kappa opioid receptor antagonism properties of the buprenorphine for a review of the kappa opioid receptor and its new directions for the treatment of pain, anxiety, depression, and drug abuse, see Khan et al. 2022 [45]. Here, OPRK1 is linked to depressive symptom measurement.